Trial pipeline · NCT06527365
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Phase 2 Active, not recruiting status last verified 2025-11
A registered clinical trial, reproduced from its ClinicalTrials.gov record. Every value on this page is a field on that record. Nothing on this page is a finding, an assessment or a recommendation.
The registered record
- Accession number
- NCT06527365
- Lead sponsor
- Veradermics, Inc. (industry)
- Registered conditions naming hair loss
- Androgenetic AlopeciaAGAMale Pattern Baldness
- Official title
- An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects With Androgenetic Alopecia
Interventions
- DrugVDPHL01
Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.
Design
- Study type
- interventional
- Phase
- Phase 2
- Allocation
- na
- Masking
- none
- Primary purpose
- treatment
- Enrolment
- 70 participants (estimated)
- Sites
- 4 locations in United States
What it measures
Changes in non-vellus Total Area Hair Count (TAHC)
Time frame: Month 12
Subjects Evaluation of Treatment Benefit
Time frame: Month 12
Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.
Who can take part
- Sex
- all
- Age
- 18 Years to 65 Years
- Healthy volunteers
- not accepted
A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.
Registered dates
- Study start
- 8 July 2024 (actual)
- Primary completion
- August 2026 (estimated)
- Study completion
- August 2026 (estimated)
- First posted
- 30 July 2024 (actual)
- Last update posted
- 6 November 2025 (actual)
"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2026-08 is a month, and rendering it as 1 August 2026 would invent a day the sponsor did not register.
Results
This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.
On this site
Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.
Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best ResultsDiffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide)How to Tell If You're Going Bald: Early Signs & Self-Assessment Guide (2026)
Where this came from
Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.
Open NCT06527365 on ClinicalTrials.gov · All 157 trials in the pipeline